跳至主要内容
临床试验/ACTRN12612000672853
ACTRN12612000672853已完成未知

A Registry of Autologous Non-Expanded Adipose Derived Stem Cells (HiQCellTM) in the Treatment of Osteoarthritis to determine prevalence of joint infections.

Regeneus Ltd0 个研究点目标入组 1,000 人开始时间: 2012年6月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
Regeneus Ltd
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Received a HiQCellTM procedure for joint osteoarthritis
  • Grade 2, 3 or early Grade 4 Osteoarthritis
  • Concurrent disease medically stable

排除标准

  • Established Grade 4 osteoarthritis
  • Major mal-alignment
  • Large osteophytes
  • Bone on Bone
  • Known allergies/ hypersensitivities to local anaesthetics or antibiotics
  • Anti-coagulant use (as below) that cannot be stopped or bleeding disorders (no use of Warfarin, Aspirin, Vitamin E, fish oil or anti-inflammatory medications 10 days before treatment)
  • Immunosuppression

研究者

发起方
Regeneus Ltd

相似试验